Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Clinical Trial ID NCT01754376

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.	J Clin Oncol	2014	1.47
2	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.	Oncotarget	2014	1.33
3	Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.	Front Immunol	2015	1.04
4	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.	Onco Targets Ther	2015	0.99
5	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.	Cancer Biol Med	2014	0.95
6	Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.	Mol Cancer Ther	2014	0.92
7	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.	Drug Des Devel Ther	2014	0.91
8	Understanding the biology of melanoma and therapeutic implications.	Hematol Oncol Clin North Am	2014	0.85
9	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.	Semin Oncol	2015	0.82
10	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.	Ther Adv Med Oncol	2015	0.78
11	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.	Trends Immunol	2016	0.75